RT Journal Article
T1 Anti-myeloperoxidase and proteinase 3 antibodies for nephritis flare prediction in anti-neutrophil cytoplasmic antibody-associated vasculitis.
A1 Rodríguez, Eva
A1 Latzke, Belén
A1 Sierra, Milagros
A1 Romera, Ana María
A1 Siedel, Diego
A1 Agraz, Irene
A1 Soler, María José
A1 García-Carro, Clara
A1 Draibe, Juliana
A1 de la Prada, Francisco José
A1 Villacorta, Javier
A1 Buxeda, Anna
A1 Sierra-Ochoa, Adriana
A1 Lozano, Inés
A1 Durán, Xavier
A1 Barrios, Clara
A1 Pascual, Julio
K1 ANCA-associated vasculitides
K1 myeloperoxidase antibodies
K1 pauci-immune necrotizing glomerulonephritis flare
K1 proteinase-3 antibodies
AB The value of myeloperoxidase (MPO) and proteinase 3 (PR3) antibody titres in the assessment of renal disease activity and flare prediction in patients with anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is not well known. We performed a retrospective study including 113 AVV patients with renal biopsy-proven pauci-immune necrotizing glomerulonephritis from seven Spanish hospitals. The main inclusion criteria were assessment of MPO antibodies using multiplex flow immunoassay and PR3 antibody measurements using immunoassay chemiluminescence with an identical range of values for all participating centres. Serum MPO antibodies 3 ± 1.2 months before relapse were higher in patients who relapsed [19.2 ± 12.2 versus 3.2 ± 5.1 antibody index (AI); P  MPO level monitoring using multiplex flow immunoassay and PR3 measurements using immunoassay chemiluminescence are useful and sensitive tools for the prediction of renal relapse in the follow-up of AAV patients with renal disease and relevant surrogate markers of renal disease activity.
YR 2022
FD 2022
LK http://hdl.handle.net/10668/19816
UL http://hdl.handle.net/10668/19816
LA en
DS RISalud
RD Apr 7, 2025